News and Events | Clinical | Eurofins-Viracor

Beyond the Patient: The Importance of Rapid Molecular Detection to Help Healthcare Facilities Stay Ahead of Candida auris

Innovation in diagnostics is driven by clinical need, scientific insight, and collaboration. This article shows how Eurofins Viracor turns early ideas into clinically relevant assays that support advanced therapies and improve patient outcomes.

IDWeek 2026 - Infectious Disease Week is October 21-24

Eurofins Viracor with be exhibiting at IDWeek 2026, booth #1719 from October 21-24 in Washington, DC...

Eurofins Viracor Launches BKV inSIGHT™ T-Cell Immunity Panel

Eurofins Viracor has launched the BKV inSIGHT™ T-Cell Immunity Panel (TCIP), a new assay that measures BK virus-specific T-cell immunity in kidney transplant patients with recent-onset BK viremia. The test provides clinicians with insight into a patient's ability to control BK virus replication, helping inform immunosuppression management and support comprehensive transplant patient monitoring.

Eurofins Viracor Expands Cytokine Testing Menu

Eurofins Viracor has launched three new plasma-based immune monitoring assays, CXCL9, CXCL10, and IL-18, for transplant and immunocompromised patients. These biomarkers provide insight into immune activation and inflammation using a minimally invasive blood sample. The tests are available with a 24-hour turnaround time and further expand Eurofins Viracor's transplant and immunology testing portfolio.

Innovation Is a Team Effort: Turning Diagnostic “Sparks” Into Clinical Impact

Innovation in diagnostics is driven by clinical need, scientific insight, and collaboration. This article shows how Eurofins Viracor turns early ideas into clinically relevant assays that support advanced therapies and improve patient outcomes.

Providing Insights Into Cancer Treatment Success

CAR T‑cell therapy is a leading immunotherapeutic option for relapsed or treatment‑resistant B‑cell cancers, using genetically modified T‑cells to recognize and eliminate malignant B‑cells. Eurofins Viracor’s ExPeCT™ CAR T‑Cell Persistence Assays provide clinicians with a validated, quantitative tool to monitor CAR T‑cell expansion and persistence, supporting informed treatment decisions and long‑term remission assessment.

ATC 2026 - American Transplant Congress

Eurofins Viracor will be exhibiting at ATC 2026, June 20-24, 2026, Booth #231, Thomas M. Menino Convention Center, Boston, MA

ISHLT 2026 - The International Society for Heart & Lung Transplantation

Eurofins Viracor will exhibit at ISHLT 2026 in Toronto, connecting attendees with cutting-edge heart and lung transplantation science, industry innovations, and networking opportunities.

Eurofins Viracor Launches ExPeCT™ anti-CD19 (obe-cel) CAR T-Cell Assay to Advance Proactive Monitoring in Next-Generation Immunotherapy

Eurofins Viracor has launched the ExPeCT™ anti-CD19 (obe-cel) CAR T-cell assay, a new diagnostic solution designed to support proactive monitoring of next-generation CAR T-cell therapies. This non-invasive blood test enables real-time assessment of CAR T-cell expansion and persistence, delivering results in approximately 24 hours after specimen receipt. Developed specifically for testing obecabtagene autoleucel (obe-cel), the assay helps clinicians gain timely, validated insights to support informed therapy decisions.

Transforming CAR T Monitoring: The Power of the ExPeCT AntiCD19 (obe-cel) Assay

Improve CAR T Monitoring - ExPeCT Anti‑CD19 (obe‑cel) Test

Discover how the ExPeCT anti‑CD19 (obe‑cel) assay enables precise CAR T‑cell expansion and persistence monitoring, delivering faster insights to guide patient care.